AbbVie Nears $11 Billion Acquisition of Apogee Therapeutics

According to the Financial Times, biopharmaceutical company AbbVie is close to completing an acquisition of Apogee Therapeutics for approximately $11 billion.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments